Colleen Channick, MD
Pulmonary Disease · Santa Monica, CANPI 1023043775
Payments from drug & device makers
What this record shows
This record is dominated by education: $8,266 of the $11,418 with a category attached, or 72.4%. Intuitive Surgical accounts for 78.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $3,654 and has fallen 83.9% since, to $590 in 2025.
Across 78 payments — averaging $146.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- Actelion Pharmaceuticals US, Inc.$878
- Bayer$459
- Noah Medical Corporation$352
- Pulmonx Corporation$259
- United Therapeutics Corporation$236
- plus $285 from 4 others
What the payments were for
- Travel & lodging$3713%
- Food & beverage$2,78124%
- Education$8,26672%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $8,948 |
| Actelion Pharmaceuticals US, Inc. | 31 | $878 |
| Bayer | 15 | $459 |
| Noah Medical Corporation | 3 | $352 |
| Pulmonx Corporation | 4 | $259 |
| United Therapeutics Corporation | 8 | $236 |
| Medtronic | 2 | $123 |
| Boston Scientific | 1 | $78 |
| Merck | 2 | $68 |
| Insmed, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,820
- ION$3,000
- GALAXY$268
- CHARTIS CATHETER$138
- ZEPHYR DELIVERY CATHETER$138
- ZEPHYR ENDOBRONCHIAL VALVE$138
- PULMONX CHARTIS TABLET CONSOLE$138
- superDimension$108
- UPTRAVI$104
- OPSUMIT$104
How this compares
$11,418 in reported general payments places this provider in the 85th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $628 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $98 |
| Prednisone | 34 | $38 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Santa Monica
- Reza RonaghiSanta Monica$390K
- Tao HeSanta Monica$214K
- Rodrigo Garcia TomeSanta Monica$92K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.